Abstract: The first output means 81 outputs a second target, which is an optimization result for a first target using an objective function generated in advance by inverse reinforcement learning based on decision making history data indicating an actual change to the target. The second output means 82 outputs a third target indicating a target resulting from further changing of the second target based on a change instruction regarding the second target accepted from the user. The data output means 83 outputs the actual change from the second target to the third target as decision making history data. The learning means 84 learns the objective function using the decision making history data.

Abstract: The target output means 91 outputs a plurality of second targets, which are optimization results for a first target using one or more objective functions generated in advance by inverse reinforcement learning based on decision making history data indicating an actual change to a target. The selection acceptance means 92 accepts a selection instruction from a user for a plurality of the output second targets. The data output means 93 outputs the actual change from the first target to the accepted second target as the decision making history data. The learning means 94 learns the objective function using the decision making history data.

Abstract: The output means 81 outputs a diagram to a display device. The input means 82 accepts designation of a change point and a change condition for the displayed diagram. The constraint generation means 83 generates a constraint for an objective function used for optimization of the diagram based on the designation. The change proposal generation means 84 generates a change proposal for the diagram by optimizing the objective function based on the generated constraint. Then, the input means 82 accepts, for each change point, the designation of a hard constraint indicating a condition that must be satisfied, or a soft constraint indicating a condition that increases a penalty according to degree of unsatisfactory, as the designation of the change condition, the constraint generation means 83 generates the constraint according to the hard constraint or soft constraint, and the output means 81 outputs the change proposal of the diagram.

Abstract: The congestion degree calculation means 81 calculates a congestion degree at a vehicle and a stop. The diagram output means 82 outputs a modified diagram in which a current diagram is modified by optimizing an objective function learned using business history data including an actual change of a diagram. The risk calculation means 83 calculates a current risk which is a risk occurring at the present time, and a modification risk which is a risk caused by modifying the diagram, based on the congestion degree. The risk output means 84 outputs the calculated current risk and the modification risk.

Abstract: A learning unit 80 includes an input unit 81, a reward function estimation unit 82, and a temporal logic structure estimation unit 83. The input unit 81 receives input of an action history of a worker who performs multiple tasks in time series. The reward function estimation unit 82 estimates a reward function for each task in time series based on the action history. The temporal logic structure estimation unit 83 estimates a temporal logic structure between tasks based on a transition condition candidate at a point in time when each estimated reward function switched.

Abstract: [Object]: To provide a compound having a novel structure effective against Hemophilus influenzae and erythromycin resistant bacteria (for example, resistant pneumococci and streptococci) as well as against conventional erythromycin sensitive bacteria. [Solution]: A novel 10a-azalide compound represented by the formula (I), a pharmaceutically acceptable salt thereof or a solvate thereof, or an intermediate for the preparation of the same. The compound of the present invention has superior antibacterial activity against Hemophilus influenzae, erythromycin resistant pneumococci and the like, and therefore, the compound can be used as a therapeutic agent of infectious diseases.

Abstract: [Object]: To provide a compound having a novel structure effective against Hemophilus influenzae and erythromycin resistant bacteria (for example, resistant pneumococci and streptococci) as well as against conventional erythromycin sensitive bacteria. [Solution]: A novel 10a-azalide compound represented by the formula (I), a pharmaceutically acceptable salt thereof or a solvate thereof, or an intermediate for the preparation of the same. The compound of the present invention has superior antibacterial activity against Hemophilus influenzae, erythromycin resistant pneumococci and the like, and therefore, the compound can be used as a therapeutic agent of infectious diseases.

Abstract: The present invention relates to compounds represented by formula (1) and a process for producing the same. The use of these compounds can realize the production of carbapenem derivatives having potent antimicrobial activity and a wide antimicrobial spectrum in a safe and cost-effective manner.

Abstract: The present invention relates to compounds represented by formula (1) and a process for producing the same. The use of these compounds can realize the production of carbapenem derivatives having potent antimicrobial activity and a wide antimicrobial spectrum in a safe and cost-effective manner.

Abstract: The present invention relates to compounds represented by formula (1) and a process for producing the same. The use of these compounds can realize the production of carbapenem derivatives having potent antimicrobial activity and a wide antimicrobial spectrum in a safe and cost-effective manner.

Abstract: Disclosed is a process for producing an imidazothiazole derivative of formula (I) useful as an intermediate for the production of carbapenem derivatives having potent antimicrobial activity and a broad antimicrobial spectrum, that is, a novel method for nicotinoylating an imidazo[5,1-b]thiazole ring at its 7-position. The process comprises reacting a compound of formula (II) with a compound of formula (III).

Abstract: The present invention relates to compounds represented by formula (1) and a process for producing the same. The use of these compounds can realize the production of carbapenem derivatives having potent antimicrobial activity and a wide antimicrobial spectrum in a safe and cost-effective manner.

Abstract: The present invention relates to compounds represented by formula (1) and a process for producing the same. The use of these compounds can realize the production of carbapenem derivatives having potent antimicrobial activity and a wide antimicrobial spectrum in a safe and cost-effective manner.

Abstract: An object of the present invention is to provide m-substituted benzoic acid derivatives having integrin ?v?3 antagonistic activity.

Abstract: An objective of the present invention is to provide highly water-soluble compounds having integrin &agr;v&bgr;3 antagonistic activity.

Abstract: An objective of the present invention is to provide compounds having integrin &agr;v&bgr;3 antagonistic activity, GP IIb/IIIa antagonistic activity, and/or human platelet aggregation inhibitory activity, and therapeutic agents for treating integrin &agr;v&bgr;3-mediated diseases and for inhibiting platelet aggregation. The derivatives according to the present invention are compounds represented by formula (I) or pharmaceutically acceptable salts or solvates thereof: wherein A represents a five- to seven-membered heterocyclic ring containing two nitrogen atoms or the like; X and Z represent CH or a nitrogen atom; R4 and R5 represent alkyl, halogen or the like; Q represents >C=O, >CH2 or the like; R6 represents H, alkyl, aralkyl or the like; R7 represents H, alkynyl or the like; R8 represents H, substituted amino or the like; R9 represents H or alkyl; m is 0 to 5; n is 0 to 4; p is 2 or 3; and q is 0 or 1.

Abstract: An objective of the present invention is to provide compounds having integrin &agr;v&bgr;3 antagonistic activity, cell adhesion inhibitory activity, GP IIb/IIIa antagonistic activity, and/or human platelet aggregation inhibitory activity, and, therapeutic agents for treating cardiovascular diseases, angiogenesis-related diseases, cerebrovascular diseases and the like and for inhibiting platelet aggregation.